Plasma stromal cell-derived factor 1α/CXCL12 level predicts long-term adverse cardiovascular outcomes in patients with coronary artery disease

Atherosclerosis

Volumn 238, Issue 1, 2015, Pages 113-118

  Ghasemzadeh, Nima ^a   Hritani, Abdul Wahab ^a   De Staercke, Christine ^b   Eapen, Danny J ^a   Veledar, Emir ^c,d   Al Kassem, Hatem ^a   Khayata, Mohamed ^a   Zafari, A Maziar ^a,e   Sperling, Laurence ^a   Hooper, Craig ^b   Vaccarino, Viola ^a,d   Mavromatis, Kreton ^a,e   Quyyumi, Arshed A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

^e ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Cardiovascular outcomes; Coronary artery disease; CXCL12; Stromal cell derived factor1

Indexed keywords

STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; CXCL12 PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORONARY ARTERY DISEASE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT RISK; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK MANAGEMENT; AGED; AREA UNDER THE CURVE; BLOOD; CARDIOVASCULAR DISEASES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME;

AGED; AREA UNDER CURVE; CARDIOVASCULAR DISEASES; CHEMOKINE CXCL12; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84913528186     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.094     Document Type: Article

References (34)

1. Askari A.T., Unzek S., Popovic Z.B., Goldman C.K., Forudi F., Kiedrowski M., Rovner A., Ellis S.G., Thomas J.D., DiCorleto P.E., Topol E.J., Penn M.S. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
2. Elmadbouh I., Haider H., Jiang S., Idris N.M., Lu G., Ashraf M. Exvivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J.Mol. Cell. Cardiol. 2007, 42:792-803.
3. Zhang G., Nakamura Y., Wang X., Hu Q., Suggs L.J., Zhang J. Controlled release of stromal cell-derived factor-1 alpha in situ increases c-kit+ cell homing to the infarcted heart. Tissue Eng. 2007, 13:2063-2071.
4. Stellos K., Langer H., Daub K., Schoenberger T., Gauss A., Geisler T., Bigalke B., Mueller I., Schumm M., Schaefer I., Seizer P., Kraemer B.F., Siegel-Axel D., May A.E., Lindemann S., Gawaz M. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. Circulation 2008, 117:206-215.
5. Abbott J.D., Huang Y., Liu D., Hickey R., Krause D.S., Giordano F.J. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004, 110:3300-3305.
6. Tang C.H., Tan T.W., Fu W.M., Yang R.S. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 2008, 29:35-43.
7. Stellos K., Ruf M., Sopova K., Kilias A., Rahmann A., Stamatelopoulos K., Jorbenadze R., Geisler T., Gawaz M., Bigalke B. Plasma levels of stromal cell-derived factor-1 in patients with coronary artery disease: effect of clinical presentation and cardiovascular risk factors. Atherosclerosis 2011, 219:913-916.
8. Wurster T., Stellos K., Haap M., Seizer P., Geisler T., Otton J., Indermuehle A., Ishida M., Schuster A., Nagel E., Gawaz M., Bigalke B. Platelet expression of stromal-cell-derived factor-1 (SDF-1): an indicator for ACS?. Int. J. Cardiol. 2013, 164:111-115.
9. Vicente-Manzanares M., Rey M., Jones D.R., Sancho D., Mellado M., Rodriguez-Frade J.M., del Pozo M.A., Yanez-Mo M., de Ana A.M., Martinez A.C., Merida I., Sanchez-Madrid F. Involvement of phosphatidylinositol 3-kinase in stromal cell-derived factor-1 alpha-induced lymphocyte polarization and chemotaxis. J.Immunol. 1999, 163:4001-4012.
10. Eapen D.J., Manocha P., Patel R.S., Hammadah M., Veledar E., Wassel C., Nanjundappa R.A., Sikora S., Malayter D., Wilson P.W., Sperling L., Quyyumi A.A., Epstein S.E. Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J.Am. Coll. Cardiol. 2013, 62:329-337.
11. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D., Katus H.A., Lindahl B., Morrow D.A., Clemmensen P.M., Johanson P., Hod H., Underwood R., Bax J.J., Bonow R.O., Pinto F., Gibbons R.J., Fox K.A., Atar D., Newby L.K., Galvani M., Hamm C.W., Uretsky B.F., Steg P.G., Wijns W., Bassand J.P., Menasche P., Ravkilde J., Ohman E.M., Antman E.M., Wallentin L.C., Armstrong P.W., Januzzi J.L., Nieminen M.S., Gheorghiade M., Filippatos G., Luepker R.V., Fortmann S.P., Rosamond W.D., Levy D., Wood D., Smith S.C., Hu D., Lopez-Sendon J.L., Robertson R.M., Weaver D., Tendera M., Bove A.A., Parkhomenko A.N., Vasilieva E.J., Mendis S. Third universal definition of myocardial infarction. Circulation 2012, 126:2020-2035.
12. Austen W.G., Edwards J.E., Frye R.L., Gensini G.G., Gott V.L., Griffith L.S., McGoon D.C., Murphy M.L., Roe B.B. Areporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975, 51:5-40.
13. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 2008, 27:157-172. Discussion 207-12.
14. Cook N.R., Ridker P.M. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann. Intern. Med. 2009, 150:795-802.
15. Yamaguchi J., Kusano K.F., Masuo O., Kawamoto A., Silver M., Murasawa S., Bosch-Marce M., Masuda H., Losordo D.W., Isner J.M., Asahara T. Stromal cell-derived factor-1 effects on exvivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003, 107:1322-1328.
16. De Falco E., Porcelli D., Torella A.R., Straino S., Iachininoto M.G., Orlandi A., Truffa S., Biglioli P., Napolitano M., Capogrossi M.C., Pesce M. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004, 104:3472-3482.
17. Moore M.A., Hattori K., Heissig B., Shieh J.H., Dias S., Crystal R.G., Rafii S. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann. N. Y. Acad. Sci. 2001, 938:36-45. Discussion 45-7.
18. Busillo J.M., Benovic J.L. Regulation of CXCR4 signaling. Biochim. Biophys. Acta 2007, 1768:952-963.
19. Ganju R.K., Brubaker S.A., Meyer J., Dutt P., Yang Y., Qin S., Newman W., Groopman J.E. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J.Biol. Chem. 1998, 273:23169-23175.
20. Liang Z., Brooks J., Willard M., Liang K., Yoon Y., Kang S., Shim H. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem. Biophys. Res. Commun. 2007, 359:716-722.
21. Wei D., Wang G., Tang C., Qiu J., Zhao J., Gregersen H., Deng L. Upregulation of SDF-1 is associated with atherosclerosis lesions induced by LDL concentration polarization. Ann. Biomed. Eng. 2012, 40:1018-1027.
22. Abi-Younes S., Sauty A., Mach F., Sukhova G.K., Libby P., Luster A.D. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ. Res. 2000, 86:131-138.
23. Massberg S., Konrad I., Schurzinger K., Lorenz M., Schneider S., Zohlnhoefer D., Hoppe K., Schiemann M., Kennerknecht E., Sauer S., Schulz C., Kerstan S., Rudelius M., Seidl S., Sorge F., Langer H., Peluso M., Goyal P., Vestweber D., Emambokus N.R., Busch D.H., Frampton J., Gawaz M. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi invivo. J.Exp. Med. 2006, 203:1221-1233.
24. Kucia M., Jankowski K., Reca R., Wysoczynski M., Bandura L., Allendorf D.J., Zhang J., Ratajczak J., Ratajczak M.Z. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J.Mol. Histol. 2004, 35:233-245.
25. Chen J., Chemaly E., Liang L., Kho C., Lee A., Park J., Altman P., Schecter A.D., Hajjar R.J., Tarzami S.T. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am. J. Pathol. 2010, 176:1705-1715.
26. Damas J.K., Waehre T., Yndestad A., Ueland T., Muller F., Eiken H.G., Holm A.M., Halvorsen B., Froland S.S., Gullestad L., Aukrust P. Stromal cell-derived factor-1alpha in unstable angina: potential antinflammatory and matrix-stabilizing effects. Circulation 2002, 106:36-42.
27. Fortunato O., Spinetti G., Specchia C., Cangiano E., Valgimigli M., Madeddu P. Migratory activity of circulating progenitor cells and serum SDF-1alpha predict adverse events in patients with myocardial infarction. Cardiovasc. Res. 2013, 100(2):192-200.
28. Subramanian S., Liu C., Aviv A., Ho J.E., Courchesne P., Muntendam P., Larson M.G., Cheng S., Wang T.J., Mehta N.N., Levy D. Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. Arterioscler. Thromb. Vasc. Biol. 2014, 34:2100-2105.
29. Stellos K., Bigalke B., Langer H., Geisler T., Schad A., Kogel A., Pfaff F., Stakos D., Seizer P., Muller I., Htun P., Lindemann S., Gawaz M. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur. Heart J. 2009, 30:584-593.
30. Camnitz W., Burdick M.D., Strieter R.M., Mehrad B., Keeley E.C. Dose-dependent effect of statin therapy on circulating CXCL12 levels in patients with hyperlipidemia. Clin. Transl. Med. 2012, 1:23.
31. Satoh K., Fukumoto Y., Nakano M., Sugimura K., Nawata J., Demachi J., Karibe A., Kagaya Y., Ishii N., Sugamura K., Shimokawa H. Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc. Res. 2009, 81:226-234.
32. Zernecke A., Bernhagen J., Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008, 117:1594-1602.
33. Burger-Kentischer A., Goebel H., Seiler R., Fraedrich G., Schaefer H.E., Dimmeler S., Kleemann R., Bernhagen J., Ihling C. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation 2002, 105:1561-1566.
34. Makino A., Nakamura T., Hirano M., Kitta Y., Sano K., Kobayashi T., Fujioka D., Saito Y., Watanabe K., Watanabe Y., Kawabata K., Obata J.E., Kugiyama K. High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 2010, 213:573-578.